Hertfordshire and West Essex ICB
Prescribing, Policies and Pathways
Prescribing, Policies and Pathways
or
| Medicine / Guideline | Indication | RAG rating | Document type | Place |
|---|---|---|---|---|
| Abdomen and Pelvis CT to rule out Pancreatic Cancer | n/a | Decision document | South and West Hertfordshire | |
| Adalimumab | Crohn's disease - moderate to severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Adalimumab | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Alcohol Related | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Amitriptyline | Irritable bowel syndrome (IBS) 2nd line unlicensed | Green | n/a | Hertfordshire and West Essex ICB |
| Anal fissure | Anal fissure | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
| Bezlotoxumab | Clostridium difficile | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Bile salts malabsorption | Bile salts malabsorption | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
| Biologic and Biosimilar Medicines | Where indicated | n/a | Patient information | Hertfordshire and West Essex ICB |
| Botulinum toxin type A | Focal spasticity, Hemi-facial spasm, Blepharospasm, Cervical dystonia, Frey’s syndrome, Chronic anal fissure, Dysphagia, Hirschsprung’s disease, Overactive bladder,Masseteric hypertrophy and temporomandibular disorders | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Budesonide - rectal (Budenofalk) | Ulcerative colitis | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Budesonide (Jorveza) | Inducing remission of eosinophilic oesophagitis | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Cholecystectomy | n/a | Clinical policy | Hertfordshire and West Essex ICB | |
| Co-danthramer | Constipation - restricted to constipation in terminally ill patients of all ages | Green | Decision document | Hertfordshire and West Essex ICB |
| Colesevelam 2nd line | Diarrhoea associated with bile acid malabsorption | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Colestyramine 1st line | Diarrhoea associated with bile acid malabsorption | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Crohn's disease | Crohn's disease - moderate to severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Darvadstrocel | Complex perianal fistulas in Crohn’s disease | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Dicycloverine | Irritable bowel syndrome (IBS) | Double Red | n/a | Hertfordshire and West Essex ICB |
| Diltiazem ointment 3rd line | Anal fissures | Green | n/a | Hertfordshire and West Essex ICB |
| Docusate sodium | Constipation | Green | n/a | Hertfordshire and West Essex ICB |
| Dupilumab | Eosinophilic oesophagitis | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Etrasimod | Ulcerative Colitis - moderate to severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Faecal Immunochemical Test (FIT) process pathway for suspected Lower GI Cancer | n/a | Clinical pathways | Hertfordshire and West Essex ICB, South and West Hertfordshire | |
| Filgotinib | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Galstones | n/a | Clinical pathways | South and West Hertfordshire | |
| Glyceryl trinitrate ointment 2nd line | Anal fissures | Green | n/a | Hertfordshire and West Essex ICB |
| Golimumab | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Hyoscine butylbromide | Irritable bowel syndrome (IBS) 1st line | Green | n/a | Hertfordshire and West Essex ICB |
| Inflammatory Bowel Disease (IBD) | n/a | Clinical pathways | East and North Hertfordshire | |
| Infliximab IV | Crohn's disease - moderate to severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Infliximab IV | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Infliximab IV biosimilar | Diarrhoea or colitis associated with Immune Checkpoint Inhibitor therapy | Red | Decision document | Hertfordshire and West Essex ICB |
| Irritable Bowel Syndrome (IBS) | n/a | n/a | South and West Hertfordshire | |
| Ispaghula husk (Fybogel) | Constipation | Green | n/a | Hertfordshire and West Essex ICB |
| Lactulose | Constipation | Green | n/a | Hertfordshire and West Essex ICB |
| Laxido | Constipation | Green | n/a | Hertfordshire and West Essex ICB |
| Liver Function Test (LFT) | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Loperamide | Diarrhoea | Green | n/a | Hertfordshire and West Essex ICB |
| Lower GI - Non Cancer Suspected | n/a | Clinical pathways | South and West Hertfordshire | |
| Macrogol | Constipation | Green | n/a | Hertfordshire and West Essex ICB |
| Mebeverine - immediate release (IR) | Irritable bowel syndrome (IBS) 1st line | Green | n/a | Hertfordshire and West Essex ICB |
| Mebeverine - modified release (MR) | Irritable bowel syndrome (IBS) | Double Red | n/a | Hertfordshire and West Essex ICB |
| Mesalazine - Octasa preferred 1st choice | Inflammatory bowel disease | Green | n/a | Hertfordshire and West Essex ICB |
| Mesalazine -Mezavant | Inflammatory bowel disease | Double Red | n/a | Hertfordshire and West Essex ICB |
| Methylnaltrexone bromide | Opioid induced bowel dysfunction | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Methylnaltrexone bromide | Constipation - opioid induced | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Mirikizumab | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Naldemedine | Constipation - opioid induced | Green | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Naloxegol | Constipation - opioid induced | Green | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Non-Alcoholic Fatty Liver Disease (NAFLD) | n/a | Clinical pathways | East and North Hertfordshire, South and West Hertfordshire | |
| Obeticholic acid | Primary biliary cholangitis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Opioid Induced Constipation | Opioid Induced Constipation | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
| Ozanimod | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Paediatric Abdominal Pain | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Paediatric Constipation | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Paediatric Diarhoea and Vomitting | n/a | n/a | Hertfordshire and West Essex ICB | |
| Peppermint oil | Irritable bowel syndrome (IBS) 1st line | Green | n/a | Hertfordshire and West Essex ICB |
| Phosphate enema (Cleen) | Constipation | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Prednisolone | All indications - soluble tablet | n/a | Patient information | Hertfordshire and West Essex ICB |
| Prednisolone enteric coated | All indications | Double Red | n/a | Hertfordshire and West Essex ICB |
| Probiotics | Treatment or prevention of diarrhoea of any cause. | Double Red | Decision document | Hertfordshire and West Essex ICB |
| Probiotics | Irritable bowel syndrome (IBS) | Double Red | n/a | Hertfordshire and West Essex ICB |
| Proton pump inhibitors - paediatric | Gastro-protection | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Rifaximin | Hepatic encephalopathy | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
| Risankizumab | Crohn's disease - moderate to severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Risankizumab | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Selective serotonin reuptake inhibitors (SSRIs) | Irritable bowel syndrome (IBS) 3rd line unlicensed | Green | n/a | Hertfordshire and West Essex ICB |
| Senna | Constipation | Green | n/a | Hertfordshire and West Essex ICB |
| Sucralfate | Gastrointestinal ulcers | Double Red | Decision document | Hertfordshire and West Essex ICB |
| Tofacitinib | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Transanal irrigation | Bowel dysfunction | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Ulcerative colitis | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Upadacitinib | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Upadacitnib | Crohn's disease - moderate to severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Ustekinumab | Crohn's disease - moderate to severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Ustekinumab | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Vedolizumab | Crohn's disease - moderate to severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Vedolizumab | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |